JANX Janux Therapeutics Inc: Accounting Value per Share

Graphic logo of Janux Therapeutics, Inc. (JANX)

The market price visualization for Janux Therapeutics (JANX) on the GURU.Markets platform is currently at 15.06. Janux Therapeutics targets collaborations with the largest pharmaceutical holdings and patients with lung or prostate cancer. The business model focuses on developing unique treatment methods, which, if successful, would secure monopoly status and colossal margins. Current funding relies on external grants and investments, as commercial products have not yet been brought to market.

JANX: Janux Pharma Net Asset Value per Share 07/04/2022 - 10/28/2026

januxrx.com - analytical breakdowns and key metrics (JANX)

- price and consensus price forecast:
Price Chart Janux Pharma|JANX - Broker Consensus Forecast
- market capitalization data:
Market Valuation Janux Therapeutics, Inc.|JANX - Business Value
- book capitalization data:
Net Assets per Single Share Janux Therapeutics|JANX - Total Stockholders' Equity|Market Value to Book Value Ratio januxrx.com|JANX - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Janux Therapeutics|JANX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Janux Therapeutics, Inc.|JANX - Company Cumulative Debt|Debt to Book Capitalization Ratio Janux Therapeutics, Inc.|JANX - Company Long-Term Debt|Company Short-Term Debt Janux Therapeutics
Fundamental company valuation:JANX - Janux Pharma
Flagship merchandise of Janux Therapeutics, Inc.

The specifics of immunotherapy development at Janux Therapeutics (JANX) determine the absolute level of the stock's book value. This indicator reflects the portion of net assets attributable to a single common share. The calculation is performed by subtracting all liabilities from the issuer's total equity. For a biotech company, such a metric serves as a financial reserve during clinical trials. Stable capital here guarantees the autonomy of research from macroeconomic fluctuations.

Competitor analysis for Janux Therapeutics

ImmunityBio Corp (IBRX) - Net Assets per Single Share|Immunocore Corp (IMCR) - Equity per Share|Accounting Value per Share Arcus Biosciences, Inc.|ZYME (zymeworks.com) - Equity per Share|Net Assets per Single Share TNGX (Tango Therapeutics, Inc.)|Net Asset Value per Share IOVA|Net Assets per Single Share Immatics Corp IMTX|Equity per Share Xencor Inc. (XNCR)|Compass Therapeutics - Book Value per Share|replimune.com - Accounting Value per Share|LYEL (Lyell Immunopharma, Inc.) - Net Assets per Single Share|IPHA: Net Asset Value per Share|pyxisoncology.com (PYXS) - Net Assets per Single Share|CGEN (Compugen) - Net Assets per Single Share|Net Assets per Single Share IOBT (IO Biotech, Inc.)|Net Asset Value per Share sutrobio.com|INKT: Book Value per Share|Book Value of One Share werewolftx.com HOWL|IMMX: Accounting Value per Share|ALXO - Net Asset Value per Share|Accounting Value per Share Cue Biopharma, Inc. (CUE)|PDSB - Accounting Value of a Share|sonnetbio.com - Book Value per Share|MAIA (MAIA Biotech) - Net Assets per Share|Net Assets per Single Share LIMN|Accounting Value per Share LVTX|Net Assets per Single Share NXTC (NextCure, Inc.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx